Dare Bioscience, Inc. (DARE) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.79

From 52W high−76.43%

Volume220616.00

Market cap$15.16M

P/E (TTM)—

P/S (TTM)11.1x

Div yield—

Key dataSep 18, 2026

Open

$0.79

From 52W high

−76.43%

Volume

220616.00

Market cap

$15.16M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.0x

P/E (TTM)

—

RSI (14)

38.2

MomentumView details →

1D Return

+3.05%

YTD Return

−59.94%

SummaryUpdated Jun 1, 2026

Daré Bioscience, Inc. (NASDAQ:DARE) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in San Diego, California. The company focuses exclusively on developing and commercializing innovative healthcare products for women's health, addressing unmet medical needs across contraception, fertility, sexual health, and vaginal health. Since its IPO in April 2014, Daré has built a diverse pipeline of 12 development-stage candidates targeting nine different women's health indications, with its first FDA-approved product <b>XACIATO</b> launched commercially in 2024 through a partnership with Organon.

Ask drillr about Dare Bioscience, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.0x

EV/Sales

6.8x

P/S (TTM)

11.1x

P/B (TTM)

−27.1x

ProfitabilityView details →

Gross Margin

−89.45%

Net Margin

−804.37%

EBITDA Margin

−672.59%

ROE (TTM)

1961.64%

ROA (TTM)

−49.12%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

+7816.73%

EPS YoY

+63.28%

FCF YoY

+0.96%

Revenue CAGR 3Y

−53.12%

EPS CAGR 3Y

—

EBITDA YoY

+47.69%

MomentumView details →

1D Return

+3.05%

YTD Return

−59.94%

1Y Return

−63.53%

RSI (14)

38.2

vs 50D SMA

−30.95%

vs 200D SMA

−56.37%

Capital & dividendView details →

Debt/Equity

−12.08x

Current Ratio

0.99x

Quick Ratio

0.99x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.20

EPS Surprise

32.59%

Beats (12Q)

11/12

Next Q EPS Est

−$0.14

Avg Surprise (4Q)

44.70%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.37M

Net Income (TTM)

−10.99M

Op. CF (TTM)

−11.29M

Next earningsNov 12, 2026 →

Latest newsMore news →

Daré Bioscience announced the peer-reviewed publication of a Phase 1 study of its topical Sildenafil Cream, 3.6% in men, showing substantially lower systemic exposure versus oral sildenafil.6d ago

Daré Bioscience announced a new NIH funding award of approximately $908,000 to advance DARE-PTB2 for the prevention of preterm birth, with potential for an additional future-year grant of approximately $1.3 million.20d ago

Similar companies

Moleculin Biotech, Inc.MBRX Passage Bio, Inc.PASG Hoth Therapeutics, Inc.HOTH Vyome Holdings, Inc.HIND SeaStar Medical Holding CorporationICU Synlogic, Inc.SYBX Find similar companies →

Latest newsMore news →

Daré Bioscience announced the peer-reviewed publication of a Phase 1 study of its topical Sildenafil Cream, 3.6% in men, showing substantially lower systemic exposure versus oral sildenafil.6d ago Daré Bioscience announced a new NIH funding award of approximately $908,000 to advance DARE-PTB2 for the prevention of preterm birth, with potential for an additional future-year grant of approximately $1.3 million.20d ago Daré Bioscience launched DARE to PLAY Sildenafil Cream, a 503B compounded version of its proprietary sildenafil cream formulation, while continuing to advance the product toward the FDA's 505(b)(2) regulatory pathway.25d ago